Published in Liver Transpl on May 01, 2000
Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. Cell Rep (2013) 1.87
Toward optimization of the linker substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem (2008) 1.10
Current perspectives on cardiac amyloidosis. Am J Physiol Heart Circ Physiol (2011) 1.04
A substructure combination strategy to create potent and selective transthyretin kinetic stabilizers that prevent amyloidogenesis and cytotoxicity. J Am Chem Soc (2010) 1.02
Toward optimization of the second aryl substructure common to transthyretin amyloidogenesis inhibitors using biochemical and structural studies. J Med Chem (2009) 0.99
Diflunisal for ATTR cardiac amyloidosis. Congest Heart Fail (2012) 0.99
Natural history and therapy of TTR-cardiac amyloidosis: emerging disease-modifying therapies from organ transplantation to stabilizer and silencer drugs. Heart Fail Rev (2015) 0.89
Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out. IUBMB Life (2015) 0.78
THAOS: gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease. Orphanet J Rare Dis (2014) 0.77
Iatrogenic amyloid polyneuropathy after domino liver transplantation. World J Hepatol (2017) 0.75
Familial (ATTR) amyloidosis misdiagnosed as the primary (AL) variant: a case report. Cases J (2009) 0.75
Results of an international, randomized trial comparing glucose metabolism disorders and outcome with cyclosporine versus tacrolimus. Am J Transplant (2007) 3.26
Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet (1993) 2.00
Low flow venovenous bypasses in small dogs and pediatric patients undergoing replacement of the liver. Surg Gynecol Obstet (1986) 2.00
Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant (2007) 1.77
Hepatic transplantation in Europe. First Report of the European Liver Transplant Registry. Lancet (1987) 1.68
Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP-met30). Clin Genet (1991) 1.60
Liver transplantation for metastatic neuroendocrine tumor disease. Transplant Proc (2003) 1.47
Improved survival in liver transplant recipients receiving prolonged-release tacrolimus in the European Liver Transplant Registry. Am J Transplant (2015) 1.46
Transplantation of autologous and allogeneic bone marrow with liver from a cadaveric donor for primary liver cancer. Transplantation (2000) 1.45
Liver transplantation in the Nordic countries, 1982-1998: changes of indications and improving results. Scand J Gastroenterol (1999) 1.45
Renal function before and long after liver transplantation in children. Transplantation (2001) 1.43
Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant (2012) 1.42
Evidence that host size determines liver size: studies in dogs receiving orthotopic liver transplants. Hepatology (1987) 1.30
Fatal deterioration of neurological disease after orthotopic liver transplantation for valproic acid-induced liver damage. Pediatr Transplant (2000) 1.22
Kinetics and dynamics of single oral doses of sirolimus in sixteen renal transplant recipients. Ther Drug Monit (1997) 1.10
Renal transplantation in the Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome. Nephrol Dial Transplant (1991) 1.08
Hereditary transthyretin amyloidosis from a Scandinavian perspective. J Intern Med (2003) 1.05
Pseudoaneurysm of the hepatic artery following liver transplantation. Transplant Proc (2006) 1.04
Liver transplantation in familial amyloidotic polyneuropathy. Follow-up of the first 20 Swedish patients. Transplantation (1995) 1.02
Liver transplantation for polycystic liver disease--indications and outcome. Transplant Proc (2003) 1.02
Hepatocyte transplantation for inherited metabolic diseases of the liver. J Intern Med (2012) 0.98
Liver uptake function measured by IODIDA clearance rate in liver transplant patients and healthy volunteers. Nucl Med Commun (1996) 0.98
Acetazolamide inhibits stimulated feline liver and gallbladder bicarbonate secretion. Acta Physiol Scand (2002) 0.97
Bile duct bacterial isolates in primary sclerosing cholangitis: a study of explanted livers. J Hepatol (1998) 0.97
Successful treatment of severe ABO antibody-mediated rejection using bortezomib: a case report. Transplant Proc (2013) 0.97
Normalization of ventilation/perfusion relationships after liver transplantation in patients with decompensated cirrhosis: evidence for a hepatopulmonary syndrome. Hepatology (1990) 0.96
A prospective, randomized, multicenter trial of tacrolimus-based therapy with or without basiliximab in pediatric renal transplantation. Am J Transplant (2006) 0.95
Influence of orthotopic liver transplantation on serum vitamin A levels in patients with chronic liver disease. Scand J Gastroenterol (1995) 0.95
Cytomegalovirus infections in liver transplant patients: incidence and outcome. Transplant Proc (1990) 0.93
MELD [corrected] score in patients accepted for liver transplantation 1994 to 2004. Transplant Proc (2006) 0.93
The incidence and diagnosis of invasive fungal infections in liver transplant recipients. Transplant Proc (1990) 0.93
Role of nitric oxide in motility and secretion of the feline hepatobiliary tract. Scand J Gastroenterol (1995) 0.91
Outcome following liver transplantation for primary sclerosing cholangitis in the Nordic countries. Scand J Gastroenterol (2003) 0.89
Improved quality of life after liver transplantation. Transplant Proc (1994) 0.88
Efficacy and safety of maribavir dosed at 100 mg orally twice daily for the prevention of cytomegalovirus disease in liver transplant recipients: a randomized, double-blind, multicenter controlled trial. Am J Transplant (2012) 0.88
Bile acid synthesis in cultured human hepatocytes: support for an alternative biosynthetic pathway to cholic acid. Hepatology (2000) 0.88
Interventional treatment of gastrointestinal neuroendocrine tumours. Digestion (2000) 0.88
Late mortality in 679 consecutive liver transplant recipients: the Gothenburg liver transplant experience. Transplant Proc (2006) 0.87
Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial. Transplant Proc (2010) 0.87
One-year glomerular filtration rate predicts graft survival in pediatric renal recipients: a randomized trial of tacrolimus vs cyclosporine microemulsion. Transplant Proc (2002) 0.86
Autosomal dominant polycystic kidney disease in a kidney transplant population. Nephrol Dial Transplant (1997) 0.86
Liver transplantation using cavoportal hemitransposition- a life-saving procedure in the presence of extensive portal vein thrombosis. Transplant Proc (2001) 0.86
Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. A randomized, placebo-controlled study. Transplantation (1995) 0.86
Monitoring of the intestinal mucosal perfusion using laser Doppler flowmetry after multivisceral transplantation. Transplant Proc (2005) 0.86
Hemolysis in ABO-compatible liver transplantation--only after O grafts? Transplant Proc (1989) 0.85
Ursodeoxycholic acid for prevention of acute rejection in liver transplant recipients. Lancet (1990) 0.85
Infectious complications after multivisceral transplantation in adults. Transplant Proc (2006) 0.84
Bone mineral status in end-stage liver disease and the effect of liver transplantation. Scand J Gastroenterol (1995) 0.83
Intraluminal polyethylene glycol stabilizes tight junctions and improves intestinal preservation in the rat. Am J Transplant (2012) 0.83
Progeny of survivors of acute lymphocytic leukemia. Acta Paediatr Scand (1979) 0.83
Erythrocyte antibodies in liver transplantation: a practical and theoretical problem. Transplant Proc (1987) 0.81
Infections in human liver recipients: different patterns early and late after transplantation. Transpl Int (1993) 0.81
Follow-up after liver transplantation for primary sclerosing cholangitis: effects on survival, quality of life, and colitis. Scand J Gastroenterol (1999) 0.81
Prophylaxis with liposomal amphotericin B (AmBisome) prevents fungal infections in liver transplant recipients: long-term results of a randomized, placebo-controlled trial. Transplant Proc (1995) 0.81
Retransplantation of the liver. Transplant Proc (2006) 0.81
Spectrum of hereditary renal disease in a kidney transplant population. Nephrol Dial Transplant (1995) 0.80
Functional and morphological relationships between the feline main pancreatic and bile duct sphincters. Gastroenterology (1990) 0.80
[Control of methicillin resistant staphylococci at the Sahlgrenska hospital. Successful control program against MRSA outbreak]. Lakartidningen (2001) 0.80
Calculation and comparison of the model for end-stage liver disease (MELD) score in patients accepted for liver transplantation in 1999 and 2004. Transplant Proc (2007) 0.80
Risk factors for deep candida infections in liver transplant recipients. Transplant Proc (1990) 0.80
Treatment with the molecular adsorbent recirculating system in patients with acute liver failure. Transplant Proc (2003) 0.80
Progressive renal impairment in liver transplant recipients on a cyclosporine-based protocol: 5 year follow-up with glomerular filtration rate measurements. Transplant Proc (1997) 0.80
Liver transplantation in patients over 60 years of age. Transpl Int (2000) 0.80
Successful ABO-incompatible liver transplantation using A2 donors. Transplant Proc (2006) 0.79
Liver transplantation in familial amyloidotic polyneuropathy (FAP). A comparative study of transplanted and non-transplanted patient's survival. Transpl Int (1998) 0.79
The liver protective effect of ischemic preconditioning may be mediated by adenosine. Transpl Int (2000) 0.79
Prognostic value of pre-transplant cardiomyopathy in Swedish liver transplanted patients for familial amyloidotic polyneuropathy. Amyloid (2011) 0.79
Primary amyloidosis with spontaneous splenic rupture, cholestasis, and liver failure treated with emergency liver transplantation. Am J Gastroenterol (1998) 0.79
Early recurrence of nephrotic syndrome (immunoglobulin m nephropathy) after renal transplantation successfully treated with combinations of plasma exchanges, immunoglobulin, and rituximab. Transplant Proc (2006) 0.79
A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients. Transplant Proc (1996) 0.79
Quality of life after paediatric kidney transplantation: a single-centre experience. Transplant Proc (2001) 0.79
Raised pressure in the bile ducts after orthotopic liver transplantation. Transpl Int (1994) 0.79
Prospective, multicenter, randomized trial to compare incidence of new-onset diabetes mellitus and glucose metabolism in patients receiving cyclosporine microemulsion versus tacrolimus after de novo kidney transplantation. Transplant Proc (2005) 0.79
Extended right-sided liver resection for colorectal liver metastases--impact of percutaneous portal venous embolisation. Eur J Surg Oncol (2006) 0.79
Toxicity of FK 506 in the cynomolgus monkey: noncorrelation with FK 506 serum levels. Transplant Proc (1991) 0.78
Pharmacological preconditioning of rat liver by up-regulation of heme oxygenase 1. Transplant Proc (2006) 0.78
Early outcome of liver transplantation using donors over 60 years of age. Transplant Proc (2001) 0.78
Change in variant transthyretin levels in patients with familial amyloidotic polyneuropathy type I following liver transplantation. Biochem Biophys Res Commun (1995) 0.78
Highly urgent liver transplantation: possible impact of donor-recipient ABO matching on the outcome after transplantation. Transplantation (2003) 0.78
Lipoprotein patterns in renal transplant patients: a comparison between FK 506 and cyclosporine A patients. Transplant Proc (1998) 0.78
Combined liver and kidney transplantation against a positive cross match in a patient with multispecific HLA-antibodies. Transplant Proc (1997) 0.78
Relevance of a positive crossmatch in liver transplantation. Transpl Int (1991) 0.78
A randomized trial of OKT3-based versus cyclosporine-based immunoprophylaxis after liver transplantation. Long-term results of a European and Australian multicenter study. Transplantation (1994) 0.78
Toxicology of FK506 in the cynomolgus monkey: a clinical, biochemical, and histopathological study. Transpl Int (1992) 0.78
Laser-Doppler flowmetry in the monitoring of the human intestinal allograft: a preliminary report. Transplant Proc (2006) 0.78
Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation (1996) 0.77
Outcome after liver transplantation for primary sclerosing cholangitis. Transplant Proc (2001) 0.77
Effect of bile flow on the absorption of tacrolimus in liver allograft transplantation. Transplant Proc (2002) 0.77